Comprehensive medication guide to Wixela Inhub including estimated pricing, availability information, side effects, and how to find it in stock at your local pharmacy.
Estimated Insurance Pricing
$0–$50 copay per 30-day fill; Wixela Inhub is typically Tier 2 (preferred generic) on most commercial and Medicare Part D formularies. Prior authorization generally not required for the generic. Brand Advair Diskus (Tier 3) may require step therapy.
Estimated Cash Pricing
$100–$230 retail per inhaler (60 doses/30-day supply) without insurance; as low as $55–$150 with GoodRx or SingleCare coupons. The 100/50 mcg strength is typically cheapest; 500/50 mcg is most expensive.
Medfinder Findability Score
82/100
Summarize with AI
On this page
Wixela Inhub is a prescription combination dry powder inhaler (DPI) containing two active medications: fluticasone propionate, an inhaled corticosteroid (ICS), and salmeterol, a long-acting beta agonist (LABA). It is manufactured by Viatris (formerly Mylan Pharmaceuticals) and was FDA-approved in January 2019 as the first generic version of Advair Diskus.
Wixela Inhub is approved for the maintenance treatment of asthma in patients age 4 and older, and for the maintenance treatment and prevention of exacerbations in adults with chronic obstructive pulmonary disease (COPD). It is used twice daily and is not a rescue inhaler.
Wixela Inhub comes in three strengths: 100/50 mcg, 250/50 mcg, and 500/50 mcg (fluticasone/salmeterol). The 250/50 mcg strength is the only one approved for COPD. Each inhaler contains 60 doses — a 30-day supply when used as directed.
We have a 99% success rate finding medications, even during nationwide shortages.
Need this medication?
Wixela Inhub works through two complementary mechanisms. The fluticasone propionate component is an inhaled corticosteroid that acts directly within the airways to reduce inflammation, swelling, and mucus production — the underlying cause of chronic airflow restriction in asthma and COPD. Fluticasone binds to glucocorticoid receptors in airway cells, suppressing the inflammatory signaling pathways that drive disease progression.
The salmeterol component is a long-acting beta2-agonist (LABA) that relaxes the smooth muscle surrounding the airways. By binding to beta2-adrenergic receptors and increasing cyclic AMP levels in muscle cells, salmeterol causes bronchodilation — widening the airways and making breathing easier. Its effects last approximately 12 hours per dose, which is why Wixela Inhub is dosed twice daily (approximately 12 hours apart).
Together, these two mechanisms address both the inflammation and the airway narrowing that characterize asthma and COPD, making the combination more effective than either drug alone for patients with moderate-to-severe disease. There is also a biochemical synergy: fluticasone upregulates beta2-receptors, making airways more responsive to salmeterol, while salmeterol activates pathways that enhance fluticasone's anti-inflammatory effects.
100/50 mcg — Dry powder inhaler (DPI)
Fluticasone propionate 100 mcg / salmeterol 50 mcg per dose. Approved for asthma (age 4+). Low-dose ICS strength.
250/50 mcg — Dry powder inhaler (DPI)
Fluticasone propionate 250 mcg / salmeterol 50 mcg per dose. Approved for asthma (age 4+) and COPD. The only strength approved for COPD.
500/50 mcg — Dry powder inhaler (DPI)
Fluticasone propionate 500 mcg / salmeterol 50 mcg per dose. Approved for asthma only (age 4+). High-dose ICS for severe or uncontrolled asthma.
Wixela Inhub is not on the FDA drug shortage list as of 2026 and maintains a solid findability profile as one of the most widely dispensed generic ICS/LABA inhalers in the country. National supply from manufacturer Viatris is adequate. Most patients are able to fill their prescription at major retail pharmacies without significant difficulty.
However, localized pharmacy-level stock gaps do occur — particularly for the high-demand 250/50 mcg strength during fall and winter respiratory seasons. These gaps are typically short-lived (1–3 business days) but can be frustrating when you're running low on your maintenance inhaler.
If your pharmacy is temporarily out, medfinder can call pharmacies near you to find which ones have your specific strength in stock — saving you the time and frustration of calling pharmacies yourself. Results are texted directly to your phone.
Wixela Inhub is not a controlled substance, which means any licensed healthcare provider with prescribing authority can prescribe it. There are no DEA scheduling restrictions, special certifications, or state-level prescribing limitations specific to this medication.
Healthcare providers who commonly prescribe Wixela Inhub include:
Telehealth availability: Since Wixela Inhub is not a controlled substance, it can be prescribed via telehealth in most states for patients with an established asthma diagnosis or stable COPD. Telehealth platforms such as Teladoc, MDLive, and major health system portals can evaluate and prescribe for appropriate cases. Note: New COPD diagnoses require in-person spirometry to confirm.
No. Wixela Inhub is not a controlled substance and is not scheduled by the DEA. It does not require special prescribing authority, does not have restrictions on the number of refills per prescription, and can be transferred between pharmacies like any standard non-controlled prescription medication.
Wixela Inhub is a prescription-only medication — meaning you do need a valid prescription from a licensed healthcare provider to obtain it, but this prescription can be issued via telehealth in most states and can be filled at any pharmacy. Unlike controlled substances, it does not require in-person visits or carry DEA-imposed refill limitations.
These side effects are commonly reported and generally manageable:
Know what you need? Skip the search.
Advair Diskus
Brand-name equivalent with identical active ingredients (fluticasone/salmeterol). Uses the Diskus device (held horizontally). Same strengths and indications. GSK savings programs cap cost at $35/month for eligible patients.
Symbicort (budesonide/formoterol)
ICS/LABA combination MDI with different active ingredients. Generic versions widely available since 2025 (~$90-$150 with discount cards). Approved for asthma (6+) and COPD. Requires dose conversion when switching from fluticasone/salmeterol.
Breo Ellipta (fluticasone furoate/vilanterol)
Once-daily ICS/LABA DPI. Brand-name only. Approved for asthma (18+) and COPD. Adherence advantage due to once-daily dosing. GSK savings programs available.
Dulera (mometasone/formoterol)
ICS/LABA MDI approved for asthma only (age 5+). Not approved for COPD. Brand-name only. Note: has experienced supply challenges in 2025-2026. Verify availability before prescribing.
Prefer Wixela Inhub? We can find it.
Strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin, cobicistat, etc.)
majorDramatically increases salmeterol exposure (ketoconazole raised salmeterol AUC 16-fold in trials) and fluticasone levels, increasing cardiovascular and adrenal suppression risk. Avoid combination.
Other LABA medications (formoterol, arformoterol, indacaterol, vilanterol)
majorContraindicated. Using two LABAs simultaneously increases risk of serious cardiovascular effects and potentially fatal outcomes.
Beta-blockers (propranolol, metoprolol, atenolol, timolol eye drops)
moderateMay antagonize salmeterol's bronchodilating effect. Non-selective beta-blockers may trigger bronchoconstriction in asthma/COPD patients. Use with caution; prefer cardioselective if necessary.
Tricyclic antidepressants (amitriptyline, nortriptyline) and MAOIs
moderatePotentiate cardiovascular effects of salmeterol including QT prolongation and arrhythmia risk. Use with extreme caution.
Loop diuretics and thiazide diuretics (furosemide, hydrochlorothiazide)
moderateAdditive hypokalemia risk with salmeterol. Monitor potassium levels in patients on both therapies.
Wixela Inhub is a well-established, FDA-proven generic of one of the most widely prescribed combination inhalers in the United States. Since its 2019 launch, it has provided millions of asthma and COPD patients with access to effective ICS/LABA therapy at a significantly lower cost than brand-name Advair Diskus. Its Tier 2 formulary status, Viatris savings programs, and broad pharmacy availability make it one of the most accessible ICS/LABA options in 2026.
If you're prescribed Wixela Inhub, the most important steps are: use it consistently twice daily, always rinse your mouth after each dose to prevent thrush, keep a rescue inhaler on hand for acute symptoms, and refill early to avoid gaps in therapy. Contact your prescriber if your symptoms aren't well controlled after 2 weeks of consistent use, or if you're using your rescue inhaler more than twice per week.
If your pharmacy is out of stock, don't wait until you run out — medfinder can check pharmacies near you and text you the results so you can get your inhaler the same day.
Medfinder Editorial Standards
Our medication guides are researched and written to help patients make informed decisions. All content is reviewed for accuracy and updated regularly. Learn more about our standards
ChatGPT
Claude
Perplexity
Grok
Gemini